Cleerly Highlights Expanded Reimbursement for AI Cardiac Plaque Analysis

According to a recent LinkedIn post from Cleerly, the company is emphasizing its AI-enabled plaque analysis technology for coronary CT angiography, which aims to distinguish between lower-risk calcified plaque and higher-risk soft, non-calcified plaque. The post indicates that this approach is positioned as more sensitive than traditional diagnostic methods in detecting dangerous plaque.

The LinkedIn post further notes that Cleerly’s technology is now associated with a new Category I CPT code and broader insurance coverage, which the company suggests extends reimbursement to a majority of insured lives in the U.S. For investors, this development could signal an inflection point for commercial adoption, potentially improving revenue visibility and reinforcing Cleerly’s competitive position in AI-driven cardiac imaging.